TY -的A2 Gronchi亚历山德罗盟——严峻,罗伯特AU -贾德森,伊恩AU -皮克,大卫盟,Seddon贝雅特丽齐PY - 2010 DA - 2010/05/31 TI -管理指南软组织肉瘤SP - 506182六世- 2010 AB -这些指导方针拟定达成共识会议后的英国肉瘤专家主持下召开的英国肉瘤组织,其目的是为了提供一个框架的多学科治疗软组织肉瘤患者。欧洲医学肿瘤学会发布的指导方针(ESMO)和美国国家综合癌症网络(机构)作为讨论的基础,根据英国临床实践和适应当地的需求。注意也采取了国家健康和临床研究所(NICE)改善结果指导(IOG)肉瘤和现有的技术评估。指导方针不是为了挑战好指导但可能存在差异,目前指导并不能反映一个国际标准的护理癌症治疗由于不断变化的本质。承认,这些指导方针将需要定期更新。附录中列出了关键的建议总结如下。任何可疑的软组织肉瘤患者应该指由专家肉瘤诊断中心和管理多学科小组。手术切除紧随其后的术后放疗是标准的优质管理肢体肉瘤虽然偶尔截肢仍然是唯一的选择。术前化疗或放疗治疗应考虑患者的边缘可切除的肿瘤。孤立的肢体灌注可能允许在某些情况下保肢截肢是唯一的选择。 Adjuvant chemotherapy is not routinely recommended but may be considered in certain specific situations. Regular follow up is recommended to assess local control and the development of metastatic disease. Single agent doxorubicin is the standard first line therapy for metastatic disease. Ifosfamide is an alternative if anthracyclines are contraindicated. Combination therapy may be considered in individual patients. Second line agents include ifosfamide, dacarbazine, trabectedin and the combination of gemcitabine + docetaxel. Surgical resection of local recurrence and pulmonary metastases should be considered in individual patients. There is specific guidance on the management of retroperitoneal and uterine sarcomas. SN - 1357-714X UR - https://doi.org/10.1155/2010/506182 DO - 10.1155/2010/506182 JF - Sarcoma PB - Hindawi Publishing Corporation KW - ER -